Telehealth Weight Loss/GLP-1 Prescribing: What Psychiatrists Can Do in North Carolina

If you’re a psychiatrist or psychiatric nurse practitioner wondering whether you can—or should—prescribe weight loss medications like semaglutide (Wegovy/Ozempic) or phentermine to your patients, you’re not alone. The explosion of GLP-1 agonists has blurred the traditional lines between psychiatry and metabolic medicine, and many mental health prescribers are asking: Is this within my scope? Will insurance cover it? What are the state rules?

Here’s the reality: Yes, you can prescribe weight loss medications—but the answer comes with important caveats about your provider type, your state’s laws, your training, and how you practice (in-person vs. telehealth). This isn’t about grabbing a piece of the weight-loss gold rush. It’s about recognizing that many of your patients struggle with obesity—often because of the psychiatric medications you prescribed—and that treating their metabolic health is increasingly inseparable from treating their mental health.

This guide will walk you through:

• Scope of practice: What psychiatrists and PMHNPs are legally allowed to do (and where the gray areas are)
• State-by-state rules: How California, Texas, Florida, New York, Pennsylvania, and Illinois regulate weight-loss prescribing and NP authority
• Telehealth compliance: Which states let you prescribe remotely and which have land mines
• Reimbursement: How to get paid for weight management services (and why Medicare’s 2025 policy shift changes everything)
• The business case: Whether adding weight management makes sense for your practice or telehealth platform

Let’s start with the fundamental question.

Can Psychiatrists Prescribe GLP-1 Medications and Weight Loss Drugs?

Short answer: Yes. Psychiatrists (MD/DO) have full prescriptive authority in every state. If you can prescribe lithium and clozapine, you can prescribe semaglutide or phentermine. The question isn’t can you—it’s should you, and how do you do it competently and compliantly.

The Scope-of-Practice Argument

Some psychiatrists worry that weight management ‘isn’t their lane.’ But consider this: you already monitor metabolic side effects of antipsychotics (weight gain, glucose dysregulation, lipid abnormalities). You already prescribe stimulants for ADHD—medications that affect appetite and weight. You already manage the whole patient, not just their neurotransmitters.

Dr. Elliott Lewis, a board-certified psychiatrist and obesity medicine specialist, puts it this way: ‘If we truly understand that metabolic and mental health systems are inseparable, then psychiatrists being involved in metabolic treatment makes complete sense.’ Many psychiatric patients develop obesity because of medications like olanzapine or quetiapine. Addressing that weight gain with a GLP-1 isn’t ‘scope creep’—it’s comprehensive care.

The key is competency. Scope of practice isn’t just about your degree; it’s about your training. If you’re prescribing weight-loss medications:

• You should understand the pharmacology (mechanism, dosing, titration schedules)
• You should know the contraindications (e.g., personal/family history of medullary thyroid cancer, gastroparesis)
• You should be able to counsel patients on lifestyle modifications (or refer to a dietitian)
• You should monitor for side effects (GI issues, gallbladder problems, rare but serious risks)

Many psychiatrists are now pursuing American Board of Obesity Medicine (ABOM) certification to formalize this expertise. ABOM is open to physicians of any specialty—you complete ~60 hours of obesity-focused CME and pass a comprehensive exam. This not only gives you the knowledge but also shields you from any ‘you’re practicing outside your specialty’ critique.

Mental Health Benefits of GLP-1s

Here’s something that might surprise you: GLP-1 medications may help mental health, not harm it. Despite early reports of possible suicidal ideation, a 2025 meta-analysis in JAMA Psychiatry found no increase in depression or suicidality with GLP-1s versus placebo. In fact, the STEP trials (semaglutide for obesity) showed slightly lower rates of depressive symptoms in the treatment group compared to controls.

Beyond safety, there’s emerging evidence that GLP-1s might aid psychiatric conditions:

• Substance use disorders: Early data suggest reduced alcohol and nicotine cravings (possibly via dopamine modulation in reward pathways)
• Binge eating disorder: Patients report decreased food obsession and impulsive eating
• Mood and anxiety: Weight loss itself often improves mood, but GLP-1s may have independent anti-inflammatory effects on the brain

This isn’t to say you should prescribe Wegovy instead of an SSRI for depression. But for a patient with treatment-resistant depression and obesity? Addressing both simultaneously could be more effective than either alone. That’s integrated care.

The Practical Reality

Most psychiatrists adding weight management to their practice do so for existing patients—not by opening a standalone diet clinic. For example:

• A 45-year-old woman on aripiprazole for bipolar disorder gains 40 pounds. You initiate low-dose semaglutide alongside lifestyle counseling.
• A 32-year-old man with ADHD and binge eating disorder asks about weight loss. You consider lisdexamfetamine (Vyvanse, FDA-approved for binge eating) or refer to a medical colleague for a GLP-1 if outside your comfort zone.
• A patient on clozapine develops metabolic syndrome. You add metformin and consider whether a GLP-1 is appropriate, coordinating with their PCP.

This is extension of care, not reinvention. You’re not becoming an endocrinologist—you’re acknowledging that psychiatric and metabolic health are linked.

Free consultations available with select providers only.

Grow your practice on Klarity

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Start seeing patients

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

PMHNPs and Weight Loss Prescribing: State-by-State Authority

For psychiatric nurse practitioners, the answer to ‘Can I prescribe weight loss medications?’ is ‘It depends where you practice.’

The National Landscape

Roughly 26 states (and D.C.) now grant nurse practitioners Full Practice Authority (FPA), meaning you can prescribe independently without physician oversight. The other ~24 states require some form of physician collaboration or supervision. For weight-loss prescribing specifically, this matters because:

1. Even in FPA states, some insurers or pharmacies may push back on high-cost GLP-1 prescriptions from NPs (wanting an MD sign-off)
2. In restricted states, your collaborative agreement must explicitly authorize weight management drugs
3. Some states (like Florida) ban all NPs from prescribing certain controlled substances via telehealth, regardless of collaboration

Let’s break down the six priority states for providers joining telehealth platforms like Klarity.

California: Transitioning to Independence (But Not Yet)

Current Status: California is phasing in NP independence via Assembly Bill 890. As of 2023, experienced NPs can practice in certain settings without standardized procedures (called ‘103’ NPs). Starting January 1, 2026, fully qualified NPs (‘104’ status) can open independent practices after completing a 3-year/4,600-hour transition period under physician supervision.

For Weight-Loss Prescribing:

• Psychiatrists (MD/DO): Full authority. No special restrictions on prescribing GLP-1s or phentermine. California doesn’t have Florida-style obesity treatment protocols, but standard of care applies (document BMI, indications, informed consent).
• PMHNPs: Until you achieve 104 status (post-transition period), you’ll need physician oversight via standardized procedures. Even after independence, California’s Corporate Practice of Medicine law means you can’t own a medical practice outright—you’ll need to work within a physician-owned entity or professional corporation. For prescribing controlled substances (like phentermine), you’ll need to ensure your furnishing privileges cover Schedule IV anorectics.
• Telehealth: California is telehealth-friendly. No state-level restrictions on remote prescribing beyond standard of care. Payment parity is mandated for commercial insurers.

Bottom Line for PMHNPs: You can prescribe weight-loss meds in California, but until 2026+ you’ll need an MD collaborator. After that, you’ll need to navigate CPOM rules (likely working for a physician-led group or MSO-structured practice).

Texas: Strict Delegation Required

Current Status: Texas is a mandatory collaboration state. All NPs must have a Prescriptive Authority Agreement (PAA) with a Texas-licensed physician to prescribe anything.

For Weight-Loss Prescribing:

• Psychiatrists: Full authority. Texas prohibits Schedule II stimulants (amphetamines) for weight loss, but phentermine (Schedule IV) and GLP-1s are fine with appropriate documentation.
• PMHNPs: You must have a PAA that explicitly lists weight-loss medications (e.g., ‘Schedule IV anorectics, GLP-1 agonists’). The PAA requires:
• Written protocols
• Monthly chart reviews by the supervising physician
• Regular face-to-face meetings (monthly or quarterly depending on chart volume)
• One MD can supervise up to 7 APRNs/PAs outside a hospital setting
• Telehealth: Texas allows telemedicine prescribing after an adequate audiovisual consultation. You must check the Prescription Monitoring Program (PMP) before prescribing controlled substances. Texas has pushed for payment parity but doesn’t yet mandate it by law for all payers (though Medicaid reimburses telehealth at par).

Bottom Line for PMHNPs: You can prescribe weight-loss meds in Texas, but only with an active PAA. Finding a collaborating physician willing to oversee weight management (especially if you’re primarily a psych NP) may require demonstrating additional training or limiting your scope to patients with co-occurring psychiatric conditions.

Florida: The Most Restrictive State

Current Status: Florida is highly regulated for both NP scope and weight-loss treatment. APRNs must have a supervisory protocol with a physician unless they qualify for limited Autonomous Practice (available only to primary care NPs, not psychiatric NPs, and even then excluding controlled substances).

For Weight-Loss Prescribing:

• Psychiatrists: Full authority, but must comply with Board of Medicine Rule 64B15-14.004:
• Document BMI ≥30 (or ≥25 + comorbidity)
• Conduct comprehensive exam (can be delegated to APRN/PA but must be documented)
• Obtain written informed consent
• Provide state-mandated ‘Weight-Loss Consumer Bill of Rights’ brochure
• Schedule follow-up every 3 months minimum to continue meds
• Check PDMP (E-FORCSE) before every controlled substance prescription
• PMHNPs: You cannot prescribe weight-loss drugs independently in Florida. You must work under a physician protocol. If your supervising MD is willing to delegate obesity treatment, they must oversee your practice (one MD can supervise up to 4 NPs typically, or 10 PAs under 2023 law changes).
• Telehealth: Here’s the big catch: Florida law prohibits prescribing controlled substances via telehealth except for psychiatric treatment, inpatient care, or acute pain. Weight loss is not an exception, meaning you cannot prescribe phentermine via telehealth to Florida patients. However, GLP-1s (Wegovy, Ozempic, etc.) are not controlled substances, so they can be prescribed via telehealth as long as you meet the standard exam and documentation requirements.

Bottom Line for PMHNPs: Florida is challenging. You’ll need MD oversight, and you cannot use controlled appetite suppressants via telehealth (limiting your toolbox to non-controlled options like GLP-1s, bupropion-naltrexone, or orlistat). Many telehealth weight-loss companies either avoid Florida for controlled drugs or partner with Florida-licensed physicians who see patients directly.

New York: Moving Toward NP Independence

Current Status: New York is a reduced practice state. NPs need a collaborative agreement with a physician initially, but after 3,600 hours of practice (roughly 2 years full-time), you can apply to practice independently under the NP Modernization Act.

For Weight-Loss Prescribing:

• Psychiatrists: Full authority. No special state obesity treatment rules beyond standard medical practice. Must check I-STOP (PMP) before prescribing Schedule II-IV controlled substances.
• PMHNPs: Early-career NPs need a collaborating physician who agrees to oversee weight management (document this in your practice protocols). Experienced NPs (post-3,600 hours) can practice independently. New York’s nursing board doesn’t restrict NPs by specialty rigidly, so a psych NP can prescribe weight-loss meds if they document competency (consider additional training). No CPOM barriers—NPs can own practices.
• Telehealth: New York is telehealth-supportive. Payment parity for telehealth mandated since 2022. No state restrictions on remote controlled substance prescribing beyond federal rules (which currently allow it through 2025 waivers).

Bottom Line for PMHNPs: If you’re an experienced NP in New York with independent practice status, you have relatively broad authority. For newer NPs, you’ll need an MD collaborator but the process is straightforward. Market-wise, NYC is saturated with weight-loss services, but upstate and rural areas have demand.

Pennsylvania: Collaboration Required (No FPA Yet)

Current Status: Pennsylvania mandates collaborative agreements for all CRNPs (Certified Registered Nurse Practitioners). No full practice authority legislation has passed as of 2025.

For Weight-Loss Prescribing:

• Psychiatrists: Full authority. No special state rules for obesity drugs.
• PMHNPs: You must have a written Collaborative Agreement with a PA-licensed physician. The agreement should outline:
• Categories of drugs you can prescribe (including Schedule IV if you plan to use phentermine)
• Consultation requirements (e.g., notify MD before starting new controlled substances)
• Chart review frequency (physician must review a percentage of your cases)
• One physician can collaborate with up to 4 NPs
• Telehealth: Pennsylvania allows telemedicine. No explicit payment parity law statewide (but Act 69 of 2020 mandates tele-mental health parity). PA Medicaid reimburses telehealth similarly to in-person.

Bottom Line for PMHNPs: You can prescribe weight-loss meds with a collaborative agreement. Finding a collaborating physician may be easier in urban areas (Philly, Pittsburgh) than rural PA. Advocacy for FPA continues—stay tuned for legislative changes.

Illinois: Full Practice Authority Available

Current Status: Illinois offers Full Practice Authority for APRNs who meet criteria: ≥4,000 clinical hours + ≥250 hours CE, then file for FPA status. APRNs without FPA need a collaborative agreement.

For Weight-Loss Prescribing:

• Psychiatrists: Full authority. No special obesity rules.
• PMHNPs:
• With FPA: You can prescribe independently, including controlled substances Schedule III-V (and Schedule II with additional 45 hours pharmacology training and a consultative relationship for the first year). You can prescribe phentermine, GLP-1s, etc., without MD oversight.
• Without FPA: You need a written collaborative agreement that specifies controlled substance prescribing authority. The collaborating MD must be in the same or related specialty (many psych NPs pair with psychiatrists or family docs willing to supervise).
• Telehealth: Illinois has strong telehealth parity laws (Telehealth Alignment Act 2021). Medicaid reimburses APRNs at 100% of physician rates (one of the few states to do this). Must check Illinois PMP for controlled substances.

Bottom Line for PMHNPs: Illinois is one of the best states for NP autonomy. If you have FPA, you’re essentially practicing like an MD in terms of prescribing (within your competency). Even without FPA, collaborative agreements are feasible. The 100% Medicaid reimbursement rate is a financial plus.

Summary Table: State-by-State NP Authority for Weight Loss

Telehealth Prescribing: Federal Waivers vs. State Land Mines

Here’s where it gets tricky. The federal government (DEA) extended COVID-era waivers allowing telemedicine prescribing of controlled substances without an initial in-person exam through December 31, 2025. This means federally, you can prescribe phentermine (Schedule IV) via a video visit.

But federal permission doesn’t override state law. And several states have their own restrictions:

Florida: The ‘No Controlled Substances via Telehealth’ Trap

Florida statute explicitly bans prescribing controlled substances via telehealth except for:

• Psychiatric disorder treatment
• Inpatient/hospice care
• Acute pain
• Addiction treatment (limited)

Weight loss is not listed. So even though federal law allows it, you cannot prescribe phentermine via telehealth to a Florida patient. (Some providers argue that if the patient has a co-occurring psychiatric diagnosis—like binge eating disorder—it might fit the ‘psychiatric disorder’ exception, but this is legally ambiguous and risky.)

The workaround? Prescribe non-controlled weight-loss medications (GLP-1s, bupropion-naltrexone, orlistat) via telehealth. Or require an in-person exam (which could be done by a Florida-licensed MD/APRN in the patient’s area) before prescribing phentermine.

Alabama, South Carolina, Idaho: Similar Restrictions

Several other states mandate an in-person exam for controlled substance prescriptions, effectively blocking pure telehealth starts. Alabama, for example, requires the initial visit to be face-to-face for controlled drugs. Providers serving these states must either:

• Arrange local exams (partner with a clinic in-state)
• Limit to non-controlled weight-loss meds
• Wait for state law changes

States That Allow It (With Caveats)

Texas, California, New York, Pennsylvania, Illinois currently allow remote controlled substance prescribing under federal waivers, as long as:

• You’re licensed in that state
• You conduct an appropriate telehealth evaluation (video preferred; some states accept audio-only in limited circumstances)
• You document the encounter and check the state PMP
• You follow any state-specific care standards (e.g., Florida’s 3-month follow-up rule if you somehow see a Florida patient in-person first)

What Happens When Federal Waivers End?

The DEA waiver is currently set to expire at the end of 2025 (it’s been extended multiple times). There’s proposed rulemaking to make some telehealth prescribing permanent, but as of early 2026, the future is uncertain. Providers should:

• Stay updated on DEA announcements (subscribe to DEA Diversion Control updates)
• Have a backup plan (e.g., if you can no longer prescribe phentermine via telehealth, pivot to GLP-1s or refer patients for an in-person med check)
• Ensure your platform or practice has compliance protocols to geofence services if needed

State-Specific Prescribing Protocols: What You Must Document

Beyond telehealth rules, many states have obesity treatment standards that apply whether you see patients in-person or remotely.

Florida: The Gold Standard (or Regulatory Gauntlet)

Florida Board of Medicine Rule 64B15-14.004 requires:

1. BMI threshold: ≥30, or ≥27 with comorbidity (hypertension, diabetes, dyslipidemia, etc.)
2. Comprehensive exam: Document history (dietary habits, weight history, medical conditions), physical exam (weight, height, BMI, blood pressure), and labs (TSH, glucose, lipids as appropriate)
3. Informed consent: Written consent discussing risks, benefits, alternatives, and that the patient will combine medication with diet/exercise
4. Follow-ups every 3 months: You must see the patient (can be via telehealth if not prescribing controlled) at least quarterly to continue meds
5. Consumer Bill of Rights: Give patient the state brochure
6. PDMP check: Before every controlled substance prescription

Florida enforces this. Clinics have been disciplined for letting patients go >3 months without follow-up or for prescribing to someone with BMI 28 without a documented comorbidity.

New Jersey: Comprehensive Workup Required

New Jersey regulations mandate:

• Complete medical history and physical exam
• Lab tests as appropriate (rule out secondary causes of obesity)
• Assessment for psychiatric conditions (this is actually an area where psychiatrists shine—you’re already equipped to screen for depression, eating disorders, etc.)
• Nutritional counseling, exercise plan, and behavior modification recommendations (you must document this or refer)

New Jersey is essentially saying ‘you can’t just write a script for Ozempic and send them on their way.’ You need to provide or coordinate comprehensive care.

Virginia: Monthly Follow-Ups Initially

Virginia requires:

• Initial physical exam
• Diet and exercise plan documented
• Follow-up within 30 days of starting medication, then regular monitoring

Mississippi: Ban on Off-Label GLP-1 Use

Mississippi took the unusual step of prohibiting off-label prescribing of GLP-1 agonists solely for weight loss (as of August 2023). You must use FDA-approved obesity versions (Wegovy, Saxenda) rather than diabetes versions (Ozempic, Mounjaro) for non-diabetic patients.

This matters because many telehealth clinics were prescribing ‘Ozempic for weight loss’ off-label (it’s cheaper than Wegovy). Mississippi said ‘no—use the approved drug.’ Providers in Mississippi risk board discipline if they prescribe Ozempic to an obese patient without diabetes.

What If Your State Doesn’t Have Specific Rules?

Most states (like California, Texas outside of federal requirements, New York, Pennsylvania, Illinois) don’t have detailed obesity prescribing protocols. You should still follow national clinical guidelines:

• Document BMI and qualifying conditions
• Obtain informed consent (discuss side effects, expected weight loss, need for lifestyle changes)
• Monitor regularly (monthly or quarterly depending on the drug and patient stability)
• Screen for contraindications (e.g., MTC history for GLP-1s, uncontrolled hypertension for phentermine)
• Check PDMP for controlled substances

Following the Endocrine Society’s Clinical Practice Guideline on Obesity or the American Board of Obesity Medicine’s standards will generally keep you compliant and defensible.

Reimbursement: Will Insurance Pay for Weight Management?

Good news: the reimbursement landscape for obesity treatment is improving fast.

Medication Coverage

GLP-1 Agonists: Many commercial insurers now cover FDA-approved obesity medications (Wegovy, Saxenda) with prior authorization. Typical PA criteria:

• BMI ≥30, or ≥27 + comorbidity (matching FDA indications)
• Documentation that patient has tried lifestyle modifications
• Sometimes, proof of enrollment in a weight management program or counseling

Some plans (like Blue Cross Blue Shield of Texas) impose 30-day supply limits initially—you prescribe one month, patient fills it, insurer monitors adherence, then approves refills if tolerated.

Medicare: Here’s the game-changer. Historically, Medicare Part D excluded weight-loss drugs. But in November 2025, the administration announced Medicare will begin covering anti-obesity medications like Wegovy and Mounjaro. Expect this to roll out in 2026. This opens treatment to millions of Medicare beneficiaries—seniors and disabled patients who previously had to pay $1,300/month out-of-pocket.

Medicaid: Coverage varies by state. Some state Medicaids already cover at least one GLP-1 for obesity; others may expand following the Medicare precedent. Check your state Medicaid formulary.

Phentermine: Generic phentermine is cheap (~$30-50/month), so most insurers cover it with minimal hassle. But remember: some insurers still view it as a ‘cosmetic’ drug and may not cover it—patients might pay cash.

Billing for Visits

You bill standard E/M codes (99202-99215 series) or psychiatric evaluation codes (90792, 90833, etc.) depending on whether you’re doing a new consult or follow-up.

For a weight management visit:

• Initial consultation (45 minutes, comprehensive history, exam, plan): Code 99204 or 99205 (might reimburse $150-250 depending on payer and region)
• Follow-up med check (15-20 minutes): Code 99213 or 99214 (~$75-120)

If you’re combining weight management with psychiatric med management in the same visit (e.g., adjusting sertraline and titrating semaglutide), document both problems. Your E/M level is based on total complexity and time.

Telehealth Modifiers: Use modifier 95 or GT (depending on payer) to indicate telehealth. In states with payment parity laws (California, New York, Illinois), you’ll be reimbursed the same as in-person. In states without parity (e.g., Texas for some commercial plans), you might see slightly lower rates—but Medicare pays telehealth at office rates through at least 2025.

Psychiatrists vs. NPs:

• Psychiatrists bill at 100% of physician fee schedules
• NPs typically get 85% of physician rates from Medicare (e.g., if a 99214 pays $110 for an MD, an NP gets ~$93)
• Exception: Illinois Medicaid reimburses NPs at 100% of physician rates—rare and provider-friendly

Medicare Billing Note

Medicare permanently expanded telehealth for mental health services (you can see patients at home with no geographic restrictions). If you’re managing a psychiatric patient’s weight, you can bill the E/M visit via telehealth and get reimbursed. Once Medicare covers GLP-1 meds in 2026, your patient’s out-of-pocket will drop significantly—making it easier to keep them on therapy.

Obesity Counseling Codes

There are specific codes for obesity counseling:

• G0447: 15 minutes face-to-face intensive behavioral therapy for obesity (BMI ≥30)
• G0473: Group sessions

These reimburse modestly (G0447 pays ~$25-30 from Medicare). Most psychiatrists don’t use these—they bill standard E/M codes instead, which reimburse better. But if you’re doing pure lifestyle counseling without medication, G0447 might be appropriate.

The Bottom Line on Reimbursement

You can get paid for weight management through insurance. The key is:

1. Document the medical necessity (BMI, comorbidities)
2. Submit prior auths for medications (most insurers require them for GLP-1s)
3. Bill appropriate E/M codes based on complexity and time
4. Use telehealth modifiers in states where virtual visits are reimbursed at parity

As anti-obesity drugs become mainstream (and Medicare/Medicaid expand coverage), the financial viability of offering weight management improves. For a psychiatrist or NP, this can be a complementary revenue stream alongside traditional psych services—especially since many of your patients need both.

The Business Case: Should You Add Weight Management to Your Practice?

Now let’s talk brass tacks. You’re a psychiatrist or PMHNP considering whether to prescribe weight-loss medications on a telehealth platform like Klarity. Does it make sense?

The ‘Why’ for Providers

1. Your Patients Need It
Many psychiatric patients struggle with obesity—often because of the medications you prescribed. Antipsychotics (olanzapine, quetiapine, risperidone) can cause 20-50 pounds of weight gain. SSRIs and mood stabilizers also contribute. If you’re not addressing this, you’re leaving a major quality-of-life issue untreated.

2. Integrated Care Works Better
Treating mental health and metabolic health together often yields better outcomes than either alone. A patient who loses 30 pounds on a GLP-1 may see their depression lift (independent of antidepressants) simply from improved self-esteem, energy, and inflammation reduction.

3. Market Demand
Obesity affects ~40% of U.S. adults. GLP-1s have exploded in popularity (semaglutide is the fastest-selling drug in history). Patients want access to these medications, and many are willing to pay out-of-pocket if insurance doesn’t cover it. Telehealth weight-loss services have grown exponentially—but most are run by MDs from other specialties (family medicine, internal medicine). There’s room for psychiatric providers who understand the mind-body connection.

4. Revenue Potential
Weight management visits can be quick and reimbursable:

• Initial consult: 30-45 minutes, bill ~$150-200
• Monthly follow-ups: 15 minutes, bill ~$75-100
• If you see 4-6 weight management patients per day (mixed with your regular psych patients), that’s an incremental $300-600/day

For NPs on a salary or per-visit model, this diversifies your patient mix and may increase your value to employers.

The ‘Why Not’ (Potential Concerns)

1. Scope Creep / Competency Concerns
Are you comfortable managing the GI side effects of GLP-1s? Do you know when to order a lipase for pancreatitis? If not, you’ll need training. Consider:

• CME courses on obesity medicine (ABOM offers a curriculum)
• Mentorship or collaboration with an endocrinologist or obesity specialist
• Limiting your scope to patients with co-occurring psych conditions (so it’s clearly within your wheelhouse)

2. Regulatory Risk
If you practice in a state with strict rules (Florida, Texas with collaboration requirements) and you cut corners on documentation or follow-ups, you risk board discipline. Weight-loss prescribing is scrutinized because of past ‘pill mill’ clinics. Make sure your practice has:

• Template notes that capture all required elements (BMI, informed consent, lifestyle counseling, PDMP checks)
• Reminder systems to schedule 3-month (or monthly) follow-ups
• Quality assurance (chart reviews if you’re supervising NPs)

3. Insurance Hassles
Prior authorizations for GLP-1s can be time-consuming. Your staff (or you) will spend time filling out PA forms, appealing denials, and dealing with supply issues (pharmacies sometimes can’t get Wegovy due to shortages). Some providers mitigate this by:

• Using a specialty pharmacy partner that handles PAs
• Offering compounded semaglutide (controversial; ensure compliance with FDA rules)
• Cash-pay options for patients who don’t want to deal with insurance

4. Liability
Any time you prescribe, there’s liability. GLP-1s are generally safe but carry risks (pancreatitis, gallbladder issues, theoretical thyroid cancer risk). Document informed consent, screen for contraindications, and follow up regularly. If a serious adverse event occurs, you want a chart that shows you practiced the standard of care.

The Sweet Spot: Integrated Psychiatric-Metabolic Care

The providers who succeed with weight management are those who position it as part of holistic psychiatric care, not a separate ‘side hustle.’ For example:

Dr. A, a psychiatrist in New York:
‘I don’t run a weight-loss clinic. But when I have a patient on an atypical antipsychotic who’s gained 40 pounds and now has prediabetes, I initiate a GLP-1 as part of their treatment plan. It’s no different than managing SSRI-induced sexual dysfunction—I’m addressing a medication side effect. I bill it as part of the psych visit, document the metabolic issues as secondary diagnoses, and coordinate with their PCP.’

Sarah, a PMHNP in Illinois with FPA:
‘I obtained my FPA status and then took a 40-hour obesity medicine course. Now I see patients for both mental health and weight management. About 30% of my

Source:

• https://www.medicaldirectorco.com/collaborative-physician-cost-weight-loss-telehealth/#:~:text=The%20answer%20is%20almost%20always,yes
• https://www.medicaldirectorco.com/collaborative-physician-cost-weight-loss-telehealth/#:~:text=Nurse%20Practitioners%20
• https://journals.lww.com/tnpj/fulltext/2024/01000/36thannualaprnlegislativeupdate__improving.6.aspx#:~:text=The%20Pennsylvania%20BON%20grants%20CRNPs%2C,more%20physicians%20to%20deliver%20healthcare
• https://journals.lww.com/tnpj/fulltext/2024/01000/36thannualaprnlegislativeupdate__improving.6.aspx#:~:text=The%20Illinois%20Department%20of%20Financial,collaborative%20agreement%20following%20a%20TTP
• https://rxagent.co/blog/telehealth-compliance-trap#:~:text=The%20DEA%20gave%20us%20the,evaluation%20at%20the%20federal%20level
• https://rxagent.co/blog/telehealth-compliance-trap#:~:text=Despite%20federal%20DEA%20waivers%20extending,traps%20for%20digital%20health%20providers
• https://rxagent.co/blog/telehealth-compliance-trap#:~:text=1.%20Florida%3A%20The%20%22No,for%20Stimulants
• https://www.mondaq.com/unitedstates/healthcare/1447512/a-changing-regulatory-and-reimbursement-landscape-for-weight-loss-drugs#:~:text=New%20Jersey%20law%20requires%20that,and%20identify%20the%20risks%20associated
• https://drlewis.com/glp-1-medications-psychiatry/#:~:text=You%20know%20these%20drugs,disorders%2C%20and%20possibly%20depression%20itself
• https://drlewis.com/glp-1-mental-health/#:~:text=Now%20let%E2%80%99s%20talk%20about%20potential,where%20things%20get%20really%20interesting